May 11, 2018   SOURCE: PR NewsWire

Global Opioid-Induced Constipation Market Spotlight 2018-2028: Valeant's Oral Relistor Poised To Face-Off Against AstraZeneca's Movantik

Global Opioid-Induced Constipation Market Spotlight 2018-2028: Valeant's Oral Relistor Poised To Face-Off Against AstraZeneca's Movantik

DUBLIN, May 11, 2018 /PRNewswire/ -- The "Market Spotlight: Opioid-Induced Constipation" report has been added to ResearchAndMarkets.com's offering.

http://mma.prnewswire.com/media/539438/Research_and_Markets_Logo.jpg

This Market Spotlight report covers the Opioid-Induced Constipation market, comprising key pipeline and marketed drugs, clinical trials, upcoming and regulatory events, patent information, a 10-year disease prevalence forecast, and licensing and acquisition deals.

Key Takeaways

    --  The approved drugs in the OIC space predominantly target opioid
        receptors, with the exception of Amitiza, a type-2 chloride channel
        activator. All of the marketed drugs are administered via the oral
        route, with one product also available in subcutaneous formulation.
    --  The majority of industry-sponsored drugs in active clinical development
        for OIC are in Phase II, with only one drug in Phase III. Therapies in
        mid-to-late-stage development for OIC focus on targets such as opioid
        receptors and guanylyl cyclase c receptor. All of the pipeline drugs are
        administered via the oral route.
    --  A Committee for Medicinal Products for Human Use (CHMP) opinion for
        Symproic is the only high-impact upcoming event in the OIC space.
    --  There was only one licensing agreement involving OIC drugs during
        2013-17.

Key Topics Covered:

KEY TAKEAWAYS

DISEASE BACKGROUND

TREATMENT
Management of OIC with laxatives
Management of OIC with opioid antagonists
Management of OIC with Amitiza, a secretagogue chloride channel activator

EPIDEMIOLOGY
Recent Prevalence Studies
Challenges

MARKETED DRUGS

PIPELINE DRUGS

KEY UPCOMING EVENTS

KEY REGULATORY EVENTS
Purdue Highlights Convenience Of New Opioid-Induced Constipation Drug Symproic
Valeant's Oral Relistor Poised To Face-Off Against AstraZeneca's Movantik

LICENSING AND ASSET ACQUISITION DEALS

PARENT PATENTS

REVENUE OPPORTUNITY

BIBLIOGRAPHY
Prescription Information

APPENDIX

For more information about this report visit https://www.researchandmarkets.com/research/2fwbfb/global?w=5

Media Contact:

Research and Markets
Laura Wood, Senior Manager
press@researchandmarkets.com

For E.S.T Office Hours Call +1-917-300-0470
For U.S./CAN Toll Free Call +1-800-526-8630
For GMT Office Hours Call +353-1-416-8900

U.S. Fax: 646-607-1907
Fax (outside U.S.): +353-1-481-1716

View original content:http://www.prnewswire.com/news-releases/global-opioid-induced-constipation-market-spotlight-2018-2028-valeants-oral-relistor-poised-to-face-off-against-astrazenecas-movantik-300647054.html

SOURCE Research and Markets